Cardiotoxicity induced by tyrosine kinase inhibitors in cancer patients
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Cancer Patients
- Registration Number
- CTRI/2018/01/011131
- Lead Sponsor
- Koilagundla Niranjan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
1 Age 18 to 60 years of either gender
2 Subjects who will be undergoing therapy with tyrosine kinase inhibitors for various cancers
3 those who are willing to give informed consent
4 those who are willing to follow study related procedures
Exclusion Criteria
1 History of cardiovascular diseases
2 history of intake of other concomitant cardiotoxic drugs
3 Pregnant and lactating females
4 History of secondary or previous history of any other malignancies
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of subjects with TKI induced cardiotoxicityTimepoint: 0,1,3,6 months
- Secondary Outcome Measures
Name Time Method Correlation of patient and disease related factorsTimepoint: 6 months;Number of subjects with specific adverse eventsTimepoint: 0,1,3,6 months